The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Uroxatral
(United States) [Available]Synonyms :
alfuzosin
Class :
Adrenergic alpha-1 antagonist
Brand Name :
Uroxatral
(United States) [Available]Synonyms :
alfuzosin
Class :
Adrenergic alpha-1 antagonist
Dosage Forms & Strengths
Capsule, Oral:
10 mg
10
mg
Capsule
Oral
once a day
Note: Use in combination with 5-alpha reductase inhibitor for patients with moderate to severely enlarged prostate (prostate volume >30ml)
No safe and efficacious dose described
Refer to adult dosing
alfuzosin: they may enhance the serum concentration of glycoprotein IIB Inhibitors
when both drugs are combined, there may be an increase in qtc interval
may decrease the metabolism when combined
may have an increased QTc-prolonging effect when combined with arsenic trioxide
azithromycin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
clofazimine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
QTc-prolonging agents: they may increase the QTc-prolonging effect of clomipramine
midostaurin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
olanzapine: they may enhance the QTc-prolonging effect of QTc-prolonging Agents
ondansetron: they may increase the QTc-prolonging effect of QTc-prolonging Agents
oxytocin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
propofol: they may increase the QTc-prolonging effect of QTc-prolonging Agents
toremifene: they may increase the QTc-prolonging effect of QTc-prolonging Agents
afatinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
by affecting intestinal metabolism, the effect of alfuzosin may be increased
calcium chloride: it may increase the risk or severity of QTc prolongation
calcium gluconate: it may increase the risk or severity of QTc prolongation
alprazolam: it may increase the risk or severity of QTc prolongation
may increase the action of CNS depressants inducing CNS depression
may increase the action of CNS depressants inducing CNS depression
may increase the action of CNS depressants inducing CNS depression
may increase the action of CNS depressants inducing CNS depression
may increase the action of CNS depressants inducing CNS depression
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
The serum concentration of alfuzosin can be increased by strong CYP3A4 inhibitors
The serum concentration of alfuzosin can be increased by strong CYP3A4 inhibitors
The serum concentration of alfuzosin can be increased by strong CYP3A4 inhibitors
The serum concentration of alfuzosin can be increased by strong CYP3A4 inhibitors
The serum concentration of alfuzosin can be increased by strong CYP3A4 inhibitors
it may enhance the qtc interval when combined with lofexidine
when both drugs are combined, there may be an increased QTC interval
when used together, azithromycin and alfuzosin both increase the QTc interval
when both drugs are combined, there may be an increased QTc interval
when used together, entrectinib and alfuzosin both increase the QTc interval
when used together, encorafenib and alfuzosin both increase the QTc interval
when both drugs are combined, there may be an increase in the QTC interval
may enhance the antihypertensive effect of other alpha1-Blockers
may enhance the antihypertensive effect of other alpha1-Blockers
may enhance the antihypertensive effect of other alpha1-Blockers
may enhance the antihypertensive effect of other alpha1-Blockers
may enhance the antihypertensive effect of other alpha1-Blockers
may increase the QTc interval when combined
may enhance the serum concentration of CYP3A4 inhibitors
may increase the risk or severity of QTc prolongation when combined
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
may have an increased QTc-prolonging effect when combined with citalopram
may have an increased QTc-prolonging effect when combined with domperidone
may have an increased QTc-prolonging effect when combined with moxifloxacin
It may enhance QTc interval when combined with pentamidine
may increase the QTc-prolonging action of QT-prolonging agents (Highest Risk)
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
thioridazine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
alfuzosin may enhance the hypotensive effect of Blood Pressure Lowering Agents
alfuzosin may enhance the hypotensive effect of Blood Pressure Lowering Agents
alfuzosin may enhance the hypotensive effect of Blood Pressure Lowering Agents
alfuzosin may enhance the hypotensive effect of Blood Pressure Lowering Agents
alfuzosin may enhance the hypotensive effect of Blood Pressure Lowering Agents
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
It may increase the hypotensive effect when combined with antihypertensive agents
alfuzosin: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
alfuzosin: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
it may enhance the risk of QTc prolongation when combined with amifampridine
It may enhance QTc interval when combined with lithium
ajmaline enhances the risk of QTc prolongation when combined with alfuzosin
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
It may diminish the level when combined with efavirenz by affecting CYP3A4 metabolism
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
The Therapeutic effectiveness of xamoterol may be diminished when administered concurrently with alfuzosin
alfuzosin's orthostatic hypotensive effects might be enhanced by levobetaxolol
it decreases the effect of hypotension of blood pressure lowering agents
it decreases the effect of hypotension of blood pressure lowering agents
it decreases the effect of hypotension of blood pressure lowering agents
it decreases the effect of hypotension of blood pressure lowering agents
it decreases the effect of hypotension of blood pressure lowering agents
It may enhance the risk of bleeding when combined with nimesulide
alfuzosin: they may enhance the serum concentration of CYP3A Inhibitors
alfuzosin: they may enhance the serum concentration of CYP3A Inhibitors
alfuzosin: they may enhance the serum concentration of CYP3A Inhibitors
alfuzosin: they may enhance the serum concentration of CYP3A Inhibitors
alfuzosin: they may enhance the serum concentration of CYP3A Inhibitors
When alfuzosin is used together with fluconazole, this leads to reduction in the alfuzosin metabolism
alfuzosin: they may increase the toxic effect of mu-opioid receptor agonists
alfuzosin: they may increase the toxic effect of mu-opioid receptor agonists
When ponesimod is used together with alfuzosin, this leads to enhanced risk or seriousness of bradycardia
When alfuzosin is used together with adenosine, this leads to enhanced risk or seriousness of QTc prolongation
alfuzosin: they may diminish the serum concentration of CYP3A4 Inducers
alfuzosin: they may diminish the serum concentration of CYP3A4 Inducers
alfuzosin: they may diminish the serum concentration of CYP3A4 Inducers
alfuzosin: they may diminish the serum concentration of CYP3A4 Inducers
alfuzosin: they may diminish the serum concentration of CYP3A4 Inducers
alfuzosin: they may increase the CNS depressant effect of CNS Depressants
alfuzosin: they may increase the CNS depressant effect of CNS Depressants
alfuzosin: they may increase the CNS depressant effect of CNS Depressants
alfuzosin: they may increase the CNS depressant effect of CNS Depressants
alfuzosin: they may increase the CNS depressant effect of CNS Depressants
When alfuzosin is used together with givinostat, this leads to enhanced risk or severity of Qtc prolongation
When indisulam is used together with alfuzosin, this leads to a reduction in alfuzosin metabolism
alfuzosin: it may increase the risk of lidoflazine
may decrease the vasoconstricting effect when combined with alpha-/beta-agonists
when coupled with diethylstilbestrol, alfuzosin's metabolism can be slowed down
When alfuzosin is used together with diazoxide, this leads to enhanced hypotensive effects of alfuzosin
alfuzosin and ciprofloxacin both increase qtc interval. Use caution/monitor Edit
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
QTc intervals are increased both by lenvatinib and alfuzosin.
the effect of alfuzosin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
when both drugs are combined, both increase the QTC interval
when both drugs are combined, both increase the QTC interval
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased QTC interval
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased QTC interval
when both drugs are combined, there may be an increase in the hypotensive effect of blood pressure-lowering agents
it may increase the risk of adverse effects
it may enhance the QTc-prolonging effect of levoketoconazole
alpha1-Blockers may reduce the vasoconstricting effect of alpha-/Beta-agonist
may enhance the hypotensive effect of calcium channel blockers
may enhance the hypotensive effect of calcium channel blockers
may enhance the hypotensive effect of calcium channel blockers
may enhance the hypotensive effect of calcium channel blockers
may enhance the hypotensive effect of calcium channel blockers
alpha1-Blockers may enhance the hypotensive effect of phosphodiesterase 5 Inhibitors
alpha1-Blockers may enhance the hypotensive effect of phosphodiesterase 5 Inhibitors
alpha1-Blockers may enhance the hypotensive effect of phosphodiesterase 5 Inhibitors
It enhances the anti-hypertensive channel blocking when combined
It enhances the anti-hypertensive channel blocking when combined
May diminish the effects of ketoprofen by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
may increase the QTc interval
glycopyrrolate inhaled and formoterol
may increase the QTc interval when combined
may increase the hypotensive effect of blood pressure lowering agents
may increase the hypotensive effect of anti-hypertensives
QTc-prolongers increase the effect of levoketoconazole
may increase the QTc-prolonging effects of QTc-prolonging agents
may increase the hypotensive effect of blood pressure-lowering agents
may increase the risk or severity of hypertension when combined
may increase the hypotensive effect of blood pressure-lowering agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may increase the CNS depressant effect of CNS Depressants
may increase the hypotensive effect of Blood Pressure Lowering Agents
QT-prolonging Miscellaneous Agents may increase the QTc-prolonging effect of chloroquine
may decrease the therapeutic efficacy of each other when combined
QT-prolonging agents increase the effect of haloperidol
It may diminish the metabolism when combined with nilvadipine
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
bunazosin (Not available in the United States)
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
may have an increased therapeutic effect when combined with alpha1-agonists
the risk of QTc prolongation may be increased
the rate of metabolism of alfuzosin may be reduced
the rate of metabolism of alfuzosin may be reduced
the rate of metabolism of alfuzosin may be reduced
moxisylyte: it may increase the hypotensive activities of alfuzosin
the therapeutic effect of pf-00610355 may be increased
the hypotensive activity of Remikiren may be increased
azatadine: it may increase the risk or severity of QTc prolongation
calcium acetate: it may increase the risk or severity of QTc prolongation
gallopamil: it may increase the risk or severity of QTc prolongation
the activity of alfuzosin may be reduced with aspirin rectal by pharmacodynamic antagonism
berotralstat: it may increase the risk or severity of QTc prolongation agents
betahistine: it may increase the risk or severity of QTc prolongation agents
acrivastine: it may increase the risk or severity of QTc prolongation agents
bilastine: it may increase the risk or severity of QTc prolongation agents
bisoprolol: it may increase the risk or severity of QTc prolongation agents
bisoxatin: it may increase the risk or severity of QTc prolongation agents
amikacin: it may increase the risk or severity of QTc prolongation agents
sulfamethoxazole: it may increase the risk or severity of QTc prolongation agents
benazepril: it may increase the risk or severity of QTc prolongation agents
bendamustine: it may increase the risk or severity of QTc prolongation agents
QT-prolonging other agents (highest Risk) may intensify amiodarone's QTc-prolonging action
QT-prolonging agents (highest Risk) may increase clofazimine's ability to prolong QTc
Frequency defined:
>10%
Retrograde ejaculated
1% to 10%
Orthostatic hypotension
Dizziness
Headache
Insomnia
Weakness
Prostate-specific antigen increased
Diarrhea
Abdominal pain
Nasal congestion
Rhinorrhea
Sinusitis
<1% Postmarketing
Hepatic insufficiency
Hypersensitivity reaction
Pharyngeal edema
Pruritis
Swollen tongue
Syncope
Urticaria
Pregnancy consideration: Not enough studies available for alfuzosin; therefore not recommended as initial therapy in pregnant women. No adverse effects were reported in animal reproductive studies.
Lactation: excretion of alfuzosin in breast milk is not known.
Pregnancy category:
Patient information leaflet
Generic Name: Alfuzosin
Pronounced: alfuzosin
Why do we use alfuzosin?
Alfuzosin is used for the treatment of enlarged prostate and may be prescribed for other reasons by a doctor.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
